International Journal of Clinical Case Reports 2024, Vol.14, No.3, 117-131 http://medscipublisher.com/index.php/ijccr 129 Pardi N., Hogan M., and Weissman D., 2020, Recent advances in mRNA vaccine technology, Current opinion in immunology, 65: 14-20. https://doi.org/10.1016/j.coi.2020.01.008 PMid:32244193 Polack F., Thomas S., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J., Marc G., Moreira E., Zerbini C., Bailey R., Swanson K., Roychoudhury S., Koury K., Li P., Kalina W., Cooper D., Frenck R., Hammitt L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D., Mather S., Dormitzer P., Şahin U., Jansen K., and Gruber W., 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, The New England Journal of Medicine, 383: 2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMid:33301246 PMCid:PMC7745181 Rosa S., Prazeres D., Azevedo A., and Marques M., 2021, mRNA vaccines manufacturing: challenges and bottlenecks, Vaccine, 39: 2190-2200. https://doi.org/10.1016/j.vaccine.2021.03.038 PMid:33771389 PMCid:PMC7987532 Sahly H., Baden L., Essink B., Doblecki-Lewis S., Martin J., Anderson E., Campbell T., Clark J., Jackson L., Fichtenbaum C., Zervos M., Rankin B., Eder F., Feldman G., Kennelly C., Han-Conrad L., Levin M., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Polakowski L., Mascola J., Ledgerwood J., Graham B., August A., Clouting H., Deng W., Han S., Leav B., Manzo D., Pajon R., Schödel F., Tomassini J., Zhou H., and Miller J., 2021, Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase, The New England Journal of Medicine, 385: 1774-1785. https://doi.org/10.1056/NEJMoa2113017 PMid:34551225 PMCid:PMC8482810 Self W., Tenforde M., Rhoads J., Gaglani M., Ginde A., Douin D., Olson S., Talbot H., Casey J., Mohr N., Zepeski A., McNeal T., Ghamande S., Gibbs K., Files D., Hager D., Shehu A., Prekker M., Erickson H., Gong M., Mohamed A., Henning D., Steingrub J., Peltan I., Brown S., Martin E., Monto A., Khan A., Hough C., Busse L., Lohuis C., Duggal A., Wilson J., Gordon A., Qadir N., Chang S., Mallow C., Rivas C., Babcock H., Kwon J., Exline M., Halasa N., Chappell J., Lauring A., Grijalva C., Rice T., Jones I., Stubblefield W., Baughman A., Womack K., Lindsell C., Hart K., Zhu Y., Mills L., Lester S., Stumpf M., Naioti E., Kobayashi M., Verani J., Thornburg N., Patel M., Calhoun N., Murthy K., Herrick J., McKillop A., Hoffman E., Zayed M., Smith M., Seattle N., Ettlinger J., Priest E., Thomas J., Arroliga A., Beeram M., Kindle R., Kozikowski L., Souza L., Ouellette S., Thornton-Thompson S., Mehkri O., Ashok K., Gole S., King A., Poynter B., Stanley N., Hendrickson A., Maruggi E., Scharber T., Jorgensen J., Bowers R., King J., Aston V., Armbruster B., Rothman R., Nair R., Chen J., Karow S., Robart E., Maldonado P., Khan M., So P., Levitt J., Perez C., Visweswaran A., Roque J., Rivera A., Angeles L., Frankel T., Goff J., Huynh D., Howell M., Friedel J., Tozier M., Driver C., Carricato M., Foster A., Nassar P., Stout L., Sibenaller Z., Walter A., Marés J., Olson L., Clinansmith B., Rivas C., Gershengorn H., McSpadden E., Truscon R., Kaniclides A., Thomas L., Bielak R., Valvano W., Fong R., Fitzsimmons W., Blair C., Valesano A., Gilbert J., Crider C., Steinbock K., Paulson T., Anderson L., Kampe C., Johnson J., Mchenry R., Blair M., Conway D., LaRose M., Landreth L., Hicks M., Parks L., Bongu J., Mcdonald D., Cass C., Seiler S., Park D., Hink T., Wallace M., Burnham C., and Arter O., 2021, Comparative effectiveness of moderna, pfizer-bionTech, and janssen (johnson & johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - united states, march-august 2021, Morbidity and Mortality Weekly Report, 70: 1337-1343. https://doi.org/10.15585/mmwr.mm7038e1 PMid:34555004 PMCid:PMC8459899 Schlake T., Thess A., Fotin‐Mleczek M., and Kallen K., 2012, Developing mRNA-vaccine technologies, RNA Biology, 9: 1319-1330. https://doi.org/10.4161/rna.22269 PMid:23064118 PMCid:PMC3597572 Sharif N., Alzahrani K., Ahmed S., and Dey S., 2021, Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis, Frontiers in Immunology, 12: 714170. https://doi.org/10.3389/fimmu.2021.714170 PMid:34707602 PMCid:PMC8542872 Surie D., DeCuir J., Zhu Y., Gaglani M., Ginde A., Douin D., Talbot H., Casey J., Mohr N., Zepeski A., McNeal T., Ghamande S., Gibbs K., Files D., Hager D., Ali H., Taghizadeh L., Gong M., Mohamed A., Johnson N., Steingrub J., Peltan I., Brown S., Martin E., Khan A., Bender W., Duggal A., Wilson J., Qadir N., Chang S., Mallow C., Kwon J., Exline M., Lauring A., Shapiro N., Columbus C., Halasa N., Chappell J., Grijalva C., Rice T., Stubblefield W., Baughman A., Womack K., Rhoads J., Hart K., Swan S., Lewis N., McMorrow M., and Self W., 2022, Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated hospitalization among immunocompetent adults aged ≥65 Years - IVY network, 18 states, september 8-november 30, 2022, Morbidity and Mortality Weekly Report, 71: 1625-1630. https://doi.org/10.15585/mmwr.mm715152e2 PMid:36580424 PMCid:PMC9812444 Tanriover M., Doğanay H., Akova M., Güner H., Azap A., Akhan S., Köse Ş., Erdinc F., Akalın E., Tabak Ö., Pullukçu H., Batum Ö., YAVUZ S., Turhan Ö., Yıldırmak M., Köksal İ., Taşova Y., Korten V., Yılmaz G., Çelen M., Altın S., Çelik I., Bayindir Y., Karaoğlan I., Yılmaz A., Özkul A., Gür H., Unal S., Akdemir-K B., Kayaaslan B., Hasanoğlu I., Dalkıran A., Aydos Ö., Cınar G., Akdemir-Kalkan I., Inkaya A., Aydın M., Çakir H., Yıldız J., Kocabıyık Ö., Arslan S., Nallı B., Demir Ö., Singil S., Ataman-Hatipoglu C., Tuncer-Ertem G., Kınıklı S., Önal U., Mete B., Dalgan G., Taşbakan M., Yamazhan T., Kömürcüoğlu B., Yalnız E., Benli A., Keskin-Sarıtaş Ç., Ertosun M., Özkan Ö., Emre S., Arıca S., Kuşçu F., Candevir A., Ertürk-Sengel B., Ayvaz F., Aksoy F., Mermutluoğlu Ç., Demir Y., Günlüoğlu G., Tural-Önür S., Kılıç-Toker A., Eren E., Otlu B., Mete A., Koçak K., Ateş H., Koca-Kalkan İ., and Aksu K., 2021, Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey, Lancet (London, England), 398: 213-222. https://doi.org/10.1016/S0140-6736(21)01429-X PMid:34246358
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==